Lunai Bioworks (LNAI) Interest & Investment Income (2014 - 2024)
Lunai Bioworks (LNAI) posted quarterly Interest & Investment Income of $126598.0 for Q3 2024, up 1411.62% year-over-year from $8375.0 in Q4 2023, and up 1411.62% quarter-over-quarter from $8375.0 in Q3 2023.
Lunai Bioworks (LNAI) Interest & Investment Income (2014 - 2024) Analysis & Trends
Lunai Bioworks' Interest & Investment Income history runs 10 years deep, the most recent figure standing at $126598.0 for Q3 2024.
- In Q3 2024, Interest & Investment Income rose 1411.62% year-over-year to $126598.0; the TTM figure through Sep 2024 stood at $143606.0 (up 23.63% YoY), while the FY2022 annual figure was $122041.0, up 826.03% from the prior year.
- Interest & Investment Income for Q3 2024 stood at $126598.0, up from $8375.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $126598.0 in Q3 2024, with the low at $1437.0 in Q1 2021.
- The 5-year median for Interest & Investment Income is $6366.5 (2021), against an average of $21154.9.
- The sharpest annual moves came in 2021 and 2022: Interest & Investment Income slumped 88.38% in 2021, then soared 2168.95% in 2022.
- Lunai Bioworks' Interest & Investment Income stood at $3066.0 in 2020, then soared by 176.81% to $8487.0 in 2021, then plunged by 64.53% to $3010.0 in 2022, then surged by 178.24% to $8375.0 in 2023, then soared by 1411.62% to $126598.0 in 2024.
- Business Quant data shows LNAI's Interest & Investment Income at $126598.0 in Q3 2024, $8375.0 in Q3 2023, and $3010.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Lunai Bioworks | 6.87 Mn | 3.72 Mn | 20,942.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 126,598.00 |
| Sep 30, 2023 | 8,375.00 |
| Dec 31, 2022 | 3,010.00 |
| Sep 30, 2022 | 5,623.00 |
| Jun 30, 2022 | 99,153.00 |
| Mar 31, 2022 | 7,291.00 |
| Dec 31, 2021 | 8,487.00 |
| Sep 30, 2021 | 7,110.00 |
| Jun 30, 2021 | 4,370.00 |
| Mar 31, 2021 | 1,437.00 |
| Dec 31, 2020 | 3,066.00 |
| Sep 30, 2020 | 4,306.00 |
| Jun 30, 2020 | 4,972.00 |
| Mar 31, 2020 | 12,371.00 |
| Dec 31, 2019 | 18,400.00 |
| Sep 30, 2019 | 14,553.00 |
| Jun 30, 2019 | 956.00 |
| Mar 31, 2019 | 8,724.00 |
| Dec 31, 2018 | 36,992.00 |
| Sep 30, 2018 | 26,815.00 |